Patient baseline characteristics in the PROMETCO study: A real-world, prospective longitudinal cohort on the continuum of care of metastatic colorectal cancer
AffiliationUniversity Medical Center Utrecht, Utrecht, Netherlands;
MetadataShow full item record
AbstractBackground:Tumour shrinkage and disease control are the primary treatment goalsfor patients with metastatic colorectal cancer (mCRC). When not possible, emphasislies in slowing disease progression and prolonging survival. Advances in the treatmentof mCRC have improved survival to an average of 30 months, but there is still apaucity of data applicable to real-world patient populations. Here we present initialbaseline patient characteristics from the PROMETCO trial (NCT03935763), thefirstinternational, prospective real-world study to investigate the continuum of care in themCRC patient population, collecting data on all patients regardless of treatment.PROMETCO will evaluate the overall survival of patients with mCRC, the patterns,effectiveness and safety of mCRC treatments, the reasons behind changes ordiscontinuation in treatment, adherence to treatment guidelines, healthcare resourceutilisation and patient-reported outcomes (PROs).Methods:Enrollment in PROMETCO began in March 2019. On 1 October 2020,baseline demographics and disease characteristics from 277 mCRC patients from 16countries were analysed. Adult patients with two disease progressions since thefirstdiagnosis of metastatic disease who were willing to receive subsequent treatmentwere included. Patients enrolled in other clinical trials, those receiving treatment forother cancers or those with insufficient mental capacity were excluded. Patients werecategorised by their molecular status (RAS/BRAF or microsatellite instability [MSI])and analysed by age, sex, Eastern Cooperative Oncology Group Performance Status(ECOG PS), metastatic status and location (side) of disease.Results:The median time between mCRC diagnosis and PROMETCO inclusion was 22months. RAS/BRAF status was divided into RAS mutant (n¼146), BRAF mutant (n¼8),RAS/BRAF wild type (WT; n¼81), unknown (n¼40) and RAS/BRAF mutant (n¼2)groups. MSI status was divided into high (n¼2), low (n¼2), stable (MSS; n¼132) andunknown (n¼141) groups. The BRAF mutant, RAS/BRAF mutant and low/high MSIgroups did not have sufficient numbers from which to draw conclusions. Baseline ageand sex demographics were similar between groups, with the exception of RAS/BRAFWT where there was a significantly higher proportion of males (58/81; 72%). Overall,248 (90%) patients had an ECOG PS of 0e1. Within groups, 137 (97%) RAS mutantpatients, 69 (86%) RAS/BRAF WT patients and 116 (92%) MSS patients had an ECOGPS of 0e1. The majority of patients (n¼243; 88%) had A higher prevalence of left-sided disease (descending colon, sigmoid colon) was seen overall (n¼121; 44%) ompared with disease of the right (cecum plus ascending colon, transverse colon:n¼77; 28%) or rectum (n¼77; 28%).Conclusions:Preliminary data from the PROMETCO trial provide key insights as to thebaseline demographics, disease characteristics and molecular status of real-worldmCRC patients. It is anticipated that PROMETCO will provide valuable data on overallsurvival, treatment patterns, effectiveness, safety, adherence to treatment guidelines,healthcare resource utilisation and PROs in this patient population.
CitationKoopman M, Pinto C, Bodoky G, Marti Marti F, Chrostek H, Raimond-Thibaut A, et al. P-137 Patient baseline characteristics in the PROMETCO study: A real-world, prospective longitudinal cohort on the continuum of care of metastatic colorectal cancer. Annals of Oncology. 2021 Jul;32:S145–6.
JournalAnnals of Oncology
TypeMeetings and Proceedings